Bangladesh · Delayed Price · Currency is BDT Pharma Aids Statistics
Total Valuation
Pharma Aids has a market cap or net worth of BDT 1.78 billion. The enterprise value is 1.76 billion.
| Market Cap | 1.78B |
| Enterprise Value | 1.76B |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Dec 8, 2025 |
Share Statistics
Pharma Aids has 3.12 million shares outstanding.
| Current Share Class | 3.12M |
| Shares Outstanding | 3.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 18.78% |
| Owned by Institutions (%) | n/a |
| Float | 2.53M |
Valuation Ratios
The trailing PE ratio is 22.96.
| PE Ratio | 22.96 |
| Forward PE | n/a |
| PS Ratio | 3.60 |
| PB Ratio | 3.67 |
| P/TBV Ratio | 3.67 |
| P/FCF Ratio | 264.63 |
| P/OCF Ratio | 28.34 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.50, with an EV/FCF ratio of 261.38.
| EV / Earnings | 22.68 |
| EV / Sales | 3.55 |
| EV / EBITDA | 15.50 |
| EV / EBIT | 16.92 |
| EV / FCF | 261.38 |
Financial Position
The company has a current ratio of 3.20, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.20 |
| Quick Ratio | 1.47 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 2.56 |
| Interest Coverage | 41.27 |
Financial Efficiency
Return on equity (ROE) is 17.19% and return on invested capital (ROIC) is 17.52%.
| Return on Equity (ROE) | 17.19% |
| Return on Assets (ROA) | 10.57% |
| Return on Invested Capital (ROIC) | 17.52% |
| Return on Capital Employed (ROCE) | 21.30% |
| Weighted Average Cost of Capital (WACC) | 4.59% |
| Revenue Per Employee | 5.27M |
| Profits Per Employee | 826,020 |
| Employee Count | 94 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 4.72 |
Taxes
In the past 12 months, Pharma Aids has paid 24.12 million in taxes.
| Income Tax | 24.12M |
| Effective Tax Rate | 23.70% |
Stock Price Statistics
The stock price has increased by +12.28% in the last 52 weeks. The beta is 0.05, so Pharma Aids's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | +12.28% |
| 50-Day Moving Average | 559.23 |
| 200-Day Moving Average | 553.59 |
| Relative Strength Index (RSI) | 49.24 |
| Average Volume (20 Days) | 16,661 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Aids had revenue of BDT 495.70 million and earned 77.65 million in profits. Earnings per share was 24.89.
| Revenue | 495.70M |
| Gross Profit | 156.50M |
| Operating Income | 104.08M |
| Pretax Income | 101.77M |
| Net Income | 77.65M |
| EBITDA | 113.58M |
| EBIT | 104.08M |
| Earnings Per Share (EPS) | 24.89 |
Balance Sheet
The company has 39.16 million in cash and 17.26 million in debt, with a net cash position of 21.89 million or 7.02 per share.
| Cash & Cash Equivalents | 39.16M |
| Total Debt | 17.26M |
| Net Cash | 21.89M |
| Net Cash Per Share | 7.02 |
| Equity (Book Value) | 485.33M |
| Book Value Per Share | 155.55 |
| Working Capital | 348.46M |
Cash Flow
In the last 12 months, operating cash flow was 62.91 million and capital expenditures -56.17 million, giving a free cash flow of 6.74 million.
| Operating Cash Flow | 62.91M |
| Capital Expenditures | -56.17M |
| Depreciation & Amortization | 9.51M |
| Net Borrowing | -325,993 |
| Free Cash Flow | 6.74M |
| FCF Per Share | 2.16 |
Margins
Gross margin is 31.57%, with operating and profit margins of 21.00% and 15.66%.
| Gross Margin | 31.57% |
| Operating Margin | 21.00% |
| Pretax Margin | 20.53% |
| Profit Margin | 15.66% |
| EBITDA Margin | 22.91% |
| EBIT Margin | 21.00% |
| FCF Margin | 1.36% |
Dividends & Yields
This stock pays an annual dividend of 3.00, which amounts to a dividend yield of 0.53%.
| Dividend Per Share | 3.00 |
| Dividend Yield | 0.53% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 12.49% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.52% |
| Earnings Yield | 4.36% |
| FCF Yield | 0.38% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 4, 2011. It was a forward split with a ratio of 10.
| Last Split Date | Dec 4, 2011 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |